In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase.
about
Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art.Activity of antimicrobial combinations against KPC-2-producing Klebsiella pneumoniae in a rat model and time-kill assay.The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniaeCarbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensionsTherapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes.Pharmacokinetic and pharmacodynamic evaluation of tigecycline.Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory.Tigecycline: Alone or in combination?New Polymyxin B Dosing Strategies To Fortify Old Allies in the War against KPC-2-Producing Klebsiella pneumoniae.Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae.Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem.Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study.In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii.Assessment of antimicrobial combinations for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae.In vitro activity of tigecycline in combination with rifampin, doripenem or ceftazidime against carbapenem-resistant Klebsiella pneumoniae bloodstream isolates.Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.
P2860
Q34327857-51E8629E-8409-4D29-BC6C-FD5CD2C59D0AQ35746001-348639C0-236A-4F05-882D-496FE0E3FE2CQ36018869-C499C607-F5F9-43B0-8448-2055B1395280Q36361921-E9E2B963-11D3-4C73-95FB-B8F69FF6E606Q37894694-F2B5C0FC-4315-4C35-A84F-2A796659F413Q37940546-89C1E103-7C64-4532-9C3D-E154B7D4BFB5Q38896040-A7A94080-85D9-476D-8AAF-60F821225DFDQ39916184-8BE5E442-375E-47F1-B384-8E5520BBB4ADQ40342720-09178359-D45D-4D0D-93D1-DE58B5FF4C33Q40533542-E8AA387D-0AE9-4F81-9D32-3E493A6C8BCFQ40913492-F3E1299C-15FB-4CAF-B9E9-B76202A726F2Q41299450-F2EBB8F9-83A8-4F9D-9010-52713BB75F86Q41833657-551F5EA1-0331-4241-B8D0-0870425AAB16Q46172822-F9AE788F-E3F9-4C41-9020-B8042844BE28Q51482172-586E29B6-7BA9-4D09-B503-4333BAE6D520Q52695014-938B679F-60B4-4E6D-97E3-1E5D126E2F5D
P2860
In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
In vitro pharmacodynamics of s ...... producing a KPC carbapenemase.
@en
type
label
In vitro pharmacodynamics of s ...... producing a KPC carbapenemase.
@en
prefLabel
In vitro pharmacodynamics of s ...... producing a KPC carbapenemase.
@en
P2093
P2860
P356
P1476
In vitro pharmacodynamics of s ...... producing a KPC carbapenemase.
@en
P2093
Anthony M Nicasio
David P Nicolau
Dora E Wiskirchen
Joseph L Kuti
Pornpan Koomanachai
P2860
P304
P356
10.1128/AAC.01253-10
P407
P577
2011-01-31T00:00:00Z